177 related articles for article (PubMed ID: 9534981)
1. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.
Hughes WT; Sillos EM; LaFon S; Rogers M; Woolley JL; Davis C; Studenberg S; Pattishall E; Freeze T; Snyder G; Staton S
J Infect Dis; 1998 Apr; 177(4):1046-56. PubMed ID: 9534981
[TBL] [Abstract][Full Text] [Related]
2. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia.
Hughes WT; LaFon SW; Scott JD; Masur H
J Infect Dis; 1995 May; 171(5):1295-301. PubMed ID: 7751706
[TBL] [Abstract][Full Text] [Related]
3. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
Hughes WT
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
[TBL] [Abstract][Full Text] [Related]
4. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.
Falloon J; Sargent S; Piscitelli SC; Bechtel C; LaFon SW; Sadler B; Walker RE; Kovacs JA; Polis MA; Davey RT; Lane HC; Masur H
Pharmacotherapy; 1999 Sep; 19(9):1050-6. PubMed ID: 10610011
[TBL] [Abstract][Full Text] [Related]
5. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
6. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; McIvor RA; Scott J; Marina R; Caldwell P
J Infect Dis; 1999 Aug; 180(2):369-76. PubMed ID: 10395851
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
8. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Contini C; Angelici E; Canipari R
J Antimicrob Chemother; 1999 Feb; 43(2):301-4. PubMed ID: 11252340
[TBL] [Abstract][Full Text] [Related]
9. Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Castro M
Semin Respir Infect; 1998 Dec; 13(4):296-303. PubMed ID: 9872626
[TBL] [Abstract][Full Text] [Related]
10. Reinstituting trimethoprim--sulfamethoxazole in patients receiving atovaquone for Pneumocystis carinii pneumonia prophylaxis.
James CW; McNelis KC; Szabo S
Am J Health Syst Pharm; 2003 Aug; 60(15):1572-4. PubMed ID: 12951757
[No Abstract] [Full Text] [Related]
11. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
Comley JC; Sterling AM
Antimicrob Agents Chemother; 1995 Apr; 39(4):806-11. PubMed ID: 7785975
[TBL] [Abstract][Full Text] [Related]
12. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Sheehan PM; Stokes DC; Yeh YY; Hughes WT
Am Rev Respir Dis; 1986 Sep; 134(3):526-31. PubMed ID: 3489425
[TBL] [Abstract][Full Text] [Related]
13. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
Groll AH; Ritter J; Müller FM
Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
[TBL] [Abstract][Full Text] [Related]
14. Employment of terbinafine against Pneumocystis carinii infection in rat models.
Contini C; Colombo D; Cultrera R; Prini E; Sechi T; Angelici E; Canipari R
Br J Dermatol; 1996 Jun; 134 Suppl 46():30-2; discussion 40. PubMed ID: 8763466
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.
Hughes WT; Gray VL; Gutteridge WE; Latter VS; Pudney M
Antimicrob Agents Chemother; 1990 Feb; 34(2):225-8. PubMed ID: 2327770
[TBL] [Abstract][Full Text] [Related]
16. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
[TBL] [Abstract][Full Text] [Related]
17. Atovaquone: a review.
Haile LG; Flaherty JF
Ann Pharmacother; 1993 Dec; 27(12):1488-94. PubMed ID: 8305784
[TBL] [Abstract][Full Text] [Related]
18. Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.
Walzer PD; Runck J; Orr S; Foy J; Steele P; White M
Antimicrob Agents Chemother; 1997 Feb; 41(2):242-50. PubMed ID: 9021174
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study.
Meyers B; Borrego F; Papanicolaou G
Liver Transpl; 2001 Aug; 7(8):750-1. PubMed ID: 11510024
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone to be marketed as oral therapy for Pneumocystis carinii pneumonia.
Clin Pharm; 1993 Mar; 12(3):175-6. PubMed ID: 8491073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
